|
|
|
Oncology Information System |
| |
Varian Medical Systems to Develop Interface Between the ARIA(TM)
Oncology Information System and the Monarch250(TM) Proton
Radiotherapy System From Still River Systems
Other Topics:
Patient Medical Data
Varian Medical Systems
May 27, 2008
Palo Alto, CA -- Varian Medical Systems (NYSE: VAR) and Still
River Systems, Inc. today announced an agreement to develop an
interface between Varian's ARIA(TM) Oncology Information System
and Still River's Monarch250(TM) Proton Beam Radiotherapy (PBRT)
System. |
| |
|
|
| |
"ARIA is a powerful oncology
information system that manages the clinical processes unique to
radiotherapy treatments for cancer," said Corey Zankowski,
Varian's senior director for product management. "In addition to
providing a complete electronic medical record for oncology,
ARIA is exceptional at recording and verifying the numerous
treatment parameters and instruction sets required for complex
radiotherapy treatments. Varian is committed to creating a
completely open environment and ensuring connectivity between
ARIA and most commonly-used radiation delivery devices,
including proton treatment systems. As such, Varian is pleased
to be developing, with the support of Still River, an interface
with the Monarch250 proton therapy system."
"It is Varian's aim to bring the familiar workflow, look and
feel of ARIA into the proton environment, to ease the transition
of staff from conventional radiotherapy to proton therapy," adds
James DeFilippi, Varian's business manager for integrated proton
solutions.
Still River Systems will provide technical assistance to Varian
engineers, who will develop the interface to allow important
"record and verify" functionality across the two systems.
"We are developing the Monarch250 proton therapy system to
support existing clinical processes. The Monarch250 ARIA
interface will allow cancer centers to integrate proton therapy
within their existing radiation therapy practices," adds Skip
Rosenthal, PhD, Still River Systems vice president, clinical
systems.
Any new ARIA interface that facilitates "record and verify"
functions with new radiotherapy delivery technologies are
subject to 510(k) clearance by the FDA, and would need such
clearance prior to any clinical deployment.
About Still River Systems
Still River Systems, based in Littleton, Massachusetts, is
dedicated to providing physicians and their patients access to
high quality, cost-effective proton therapy solutions, and to
help establish this superior treatment modality as a standard of
care for patients worldwide. Still River Systems is developing
the Monarch250, an affordable, precise and compact proton
therapy system for cancer treatment. This system has not yet
been cleared by the FDA for commercial use in clinical therapy.
For more information on Still River Systems and the Monarch250
Proton Therapy System, please call 978-540- 1500 or visit their
website @ http://www.StillRiverSystems.com.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the
world's leading manufacturer of medical devices and software for
treating cancer and other medical conditions with radiotherapy,
radiosurgery, proton therapy, and brachytherapy. The company
supplies informatics software for managing comprehensive cancer
clinics, radiotherapy centers and medical oncology practices.
Varian is a premier supplier of tubes and digital detectors for
X-ray imaging in medical, scientific, and industrial
applications and also supplies X-ray imaging products for cargo
screening and industrial inspection. Varian Medical Systems
employs approximately 4,600 people who are located at
manufacturing sites in North America and Europe and in its 60
sales and support offices around the world. For more
information, visit http://www.varian.com/.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform
Act of 1995, which provides a "safe harbor" for these types of
statements. These forward-looking statements regarding future
business, events, plans, objectives, expectations, and other
similar matters, including, but not limited to, statements using
the terms "is committed to creating," "ensuring," and "are
developing," "will allow," and "would need" are subject to risks
and uncertainties that could cause the actual results of Varian
Medical Systems, Inc. to differ materially from management's
current expectations. These risks and uncertainties include,
without limitation, product demand and market acceptance risks;
technological innovation, development of new generation of
products and enhancements to existing products; the ability to
procure appropriate FDA clearances for new products; and other
risks detailed in Varian Medical Systems, Inc. filings with the
Securities and Exchange Commission. Varian Medical Systems, Inc.
assumes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future
events, or otherwise. |
| |
|
|
| |
|
|
